Literature DB >> 20851863

Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy.

Angela Siciliano1, Giorgio Malpeli, Orah S Platt, Christophe Lebouef, Anne Janin, Aldo Scarpa, Oliviero Olivieri, Eliana Amato, Roberto Corrocher, Yves Beuzard, Lucia De Franceschi.   

Abstract

BACKGROUND: Sickle cell disease, a genetic red cell disorder inherited in an autosomal recessive manner, occurs throughout the world. Hepatic dysfunction and liver damage may be present in sickle cell disease, but the pathogenesis of these conditions is only partially understood. DESIGN AND METHODS: Transgenic mice with sickle cell disease (SAD mice) and wild-type mice were exposed to an ischemic/reperfusion stress. The following parameters were evaluated: hematologic profile, transaminase and bilirubin levels, liver histopathology, and mRNA levels of nuclear factor-κB p65, endothelial nitric oxide synthase, inducible nitric oxide synthase, heme oxygenase-1 and phosphodiesterase-1, -2, -3, and -4 genes in hepatocytes obtained by laser-capture microdissection. Immunoblotting was used to analyze the expression of the following proteins: nuclear factor-κB p65 and phospho-nuclear factor-κB p65, heme oxygenase-1, biliverdin reductase, heat shock protein-70, heat shock protein-27 and peroxiredoxin-6. A subgroup of SAD mice was treated with the phosphodiesterase-4 inhibitor rolipram (30 mg/Kg/day by gavage) during the ischemic/reperfusion protocol.
RESULTS: In SAD mice the ischemic/reperfusion stress induced liver damage compatible with sickle cell disease hepatopathy, which was associated with: (i) lack of hypoxia-induced nuclear factor-κB p65 activation; (ii) imbalance in the endothelial/inducible nitric oxide synthase response to ischemic/reperfusion stress; (iii) lack of hypoxia-induced increased expression of heme oxygenase-1/biliverdin reductase paralleled by a compensatory increased expression of heat shock proteins 70 and 27 and peroxiredoxin-6; and (iv) up-regulation of the phosphodiesterase-1, -2, -3, and -4 genes. In SAD mice the phosphodiesterase-4 inhibitor rolipram attenuated the ischemic/reperfusion-related microcirculatory dysfunction, reduced the inflammatory cell infiltration and induced the heme oxygenase-1/biliverdin reductase cytoprotective systems.
CONCLUSIONS: In SAD mice, sickle cell hepatopathy is associated with perturbed nuclear factor-κB p65 signaling with an imbalance of endothelial/inducible nitric oxide synthase levels, lack of heme oxygenase-1/biliverdin reductase expression and up-regulation of two novel cytoprotective systems: heat shock protein-27 and peroxiredoxin-6.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851863      PMCID: PMC3012761          DOI: 10.3324/haematol.2010.028506

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  46 in total

Review 1.  Sickle cell hepatopathy.

Authors:  S Banerjee; C Owen; S Chopra
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

2.  Laser-capture microdissection.

Authors:  Virginia Espina; Julia D Wulfkuhle; Valerie S Calvert; Amy VanMeter; Weidong Zhou; George Coukos; David H Geho; Emanuel F Petricoin; Lance A Liotta
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

3.  Ischemia and reperfusion of liver induces eNOS and iNOS expression: effects of a NO donor and NOS inhibitor.

Authors:  Hen I Lin; David Wang; Fur-Jiang Leu; Chao-Fuh Chen; Hsing I Chen
Journal:  Chin J Physiol       Date:  2004-09-30       Impact factor: 1.764

4.  Sickle cell hepatopathy.

Authors:  T W Sheehy
Journal:  South Med J       Date:  1977-05       Impact factor: 0.954

5.  The role of the cysteine residue in the chaperone and anti-apoptotic functions of human Hsp27.

Authors:  Nagarekha Pasupuleti; Mahesha Gangadhariah; Smitha Padmanabha; Puttur Santhoshkumar; Ram H Nagaraj
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

6.  Vascular lesions of the liver in sickle cell disease. A clinicopathological study in 26 living patients.

Authors:  F Charlotte; D Bachir; M Nénert; P Mavier; F Galactéros; D Dhumeaux; E S Zafrani
Journal:  Arch Pathol Lab Med       Date:  1995-01       Impact factor: 5.534

Review 7.  Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection.

Authors:  Narci C Teoh; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2003-08       Impact factor: 4.029

8.  Role of nitric oxide in the expression of hepatic vascular stress genes in response to sepsis.

Authors:  Hyun-Ae Eum; Sang-Won Park; Sun-Mee Lee
Journal:  Nitric Oxide       Date:  2007-08-19       Impact factor: 4.427

9.  Ischemic hepatitis.

Authors:  T E Bynum; J K Boitnott; W C Maddrey
Journal:  Dig Dis Sci       Date:  1979-02       Impact factor: 3.199

10.  Hepatic dysfunction in sickle cell disease: a new system of classification based on global assessment.

Authors:  Philip A Berry; Timothy J S Cross; Swee Lay Thein; Bernard C Portmann; Julia A Wendon; John B Karani; Michael A Heneghan; Adrian Bomford
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-27       Impact factor: 11.382

View more
  11 in total

1.  Vascular risk assessment in patients with sickle cell disease.

Authors:  Claudia R Morris
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

2.  Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease.

Authors:  Brian T Kalish; Alessandro Matte; Immacolata Andolfo; Achille Iolascon; Olga Weinberg; Alessandra Ghigo; James Cimino; Angela Siciliano; Emilio Hirsch; Enrica Federti; Mark Puder; Carlo Brugnara; Lucia De Franceschi
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

Review 3.  The multifaceted role of ischemia/reperfusion in sickle cell anemia.

Authors:  Robert P Hebbel; John D Belcher; Gregory M Vercellotti
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

4.  MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice.

Authors:  John D Belcher; Mark Young; Chunsheng Chen; Julia Nguyen; Kenneth Burhop; Phuc Tran; Gregory M Vercellotti
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

5.  Mn porphyrins as a novel treatment targeting sickle cell NOXs to reverse and prevent acute vaso-occlusion in vivo.

Authors:  Madhan Thamilarasan; Rodolfo Estupinan; Ines Batinic-Haberle; Rahima Zennadi
Journal:  Blood Adv       Date:  2020-06-09

6.  Sustained treatment of sickle cell mice with haptoglobin increases HO-1 and H-ferritin expression and decreases iron deposition in the kidney without improvement in kidney function.

Authors:  Patricia A Shi; Erika Choi; Narendranath R Chintagari; Julia Nguyen; Xinhua Guo; Karina Yazdanbakhsh; Narla Mohandas; Abdu I Alayash; Elizabeth A Manci; John D Belcher; Gregory M Vercellotti
Journal:  Br J Haematol       Date:  2016-08-10       Impact factor: 6.998

7.  Magnesium for treating sickle cell disease.

Authors:  Nan Nitra Than; Htoo Htoo Kyaw Soe; Senthil K Palaniappan; Adinegara Bl Abas; Lucia De Franceschi
Journal:  Cochrane Database Syst Rev       Date:  2019-09-09

8.  Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease.

Authors:  Lucia De Franceschi; Robert S Franco; Mariarita Bertoldi; Carlo Brugnara; Alessandro Matté; Angela Siciliano; Adam J Wieschhaus; Athar H Chishti; Clinton H Joiner
Journal:  FASEB J       Date:  2012-10-19       Impact factor: 5.191

9.  MEK inhibitors, novel anti-adhesive molecules, reduce sickle red blood cell adhesion in vitro and in vivo, and vasoocclusion in vivo.

Authors:  Rahima Zennadi
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

10.  Sickle cell disease mice have cerebral oxidative stress and vascular and white matter abnormalities.

Authors:  Alfia Khaibullina; Luis E F Almeida; Sayuri Kamimura; Patricia M Zerfas; Meghann L Smith; Sebastian Vogel; Paul Wakim; Olavo M Vasconcelos; Martha M Quezado; Iren Horkayne-Szakaly; Zenaide M N Quezado
Journal:  Blood Cells Mol Dis       Date:  2020-09-04       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.